| Identification | Back Directory | [Name]
BroMosporine | [CAS]
1619994-69-2 | [Synonyms]
BroMosporine
N-[6-(3-Methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate
ethyl 3-Methyl-6-(4-Methyl-3-(MethylsulfonaMido)phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-ylcarbaMate | [Molecular Formula]
C17H20N6O4S | [MDL Number]
MFCD26142669 | [MOL File]
1619994-69-2.mol | [Molecular Weight]
404.443 |
| Chemical Properties | Back Directory | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
Soluble in DMSO (up to 25 mg/ml) | [form ]
solid | [pka]
6.21±0.46(Predicted) | [color ]
Off-white | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. | [InChI]
1S/C17H20N6O4S/c1-5-27-17(24)18-15-9-14(21-23-11(3)19-20-16(15)23)12-7-6-10(2)13(8-12)22-28(4,25)26/h6-9,22H,5H2,1-4H3,(H,18,24) | [InChIKey]
UYBRROMMFMPJAN-UHFFFAOYSA-N | [SMILES]
CC(C(NS(C)(=O)=O)=C1)=CC=C1C2=NN3C(C(NC(OCC)=O)=C2)=NN=C3C |
| Hazard Information | Back Directory | [Description]
Bromosporine (1619994-69-2) is a potent pan-Bromodomain (BRD) inhibitor.1?Bromosporine was able to reactivate HIV-1 replication in different latency models.2 | [Uses]
Bromosporine is a broad spectrum inhibitor for bromodomains. | [in vivo]
Bromosporine (100 mg/kg; i.p.; daily for 10 days) shows better antitumor activity than individual when co-treated with 5-Fluorouracil.html" class="link-product" target="_blank">5-FU (HY-90006)[1]. | Animal Model: | Female BALB/c nude mice (5-6 weeks; injected with 1?×?106?cells/100?μL of HT116?cells)[1] | | Dosage: | 100 mg/kg | | Administration: | i.p.; daily for 10 days | | Result: | Exhibited better antitumor activity than individual Bromosporine or 5-FU (HY-90006) when co-treated with the two agent. |
| [target]
bromodomain | [IC 50]
HIV-1 | [storage]
Store at +4°C | [References]
1) Picaud?et al.?(2016),?Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia; Sci. Adv.?2?e1600760
2) Pan?et al.?(2017),?The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells; Oncotarget?8?94104 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|